Cellectis S.A.

2.91-0.3000-9.35%Vol 174.11K1Y Perf -80.26%
Jun 28th, 2022 16:00 DELAYED
BID2.80 ASK2.95
Open3.07 Previous Close3.21
Pre-Market- After-Market2.91
 - -  - -%
Target Price
15.71 
Analyst Rating
Moderate Buy 2.14
Potential %
439.86 
Finscreener Ranking
★★★     48.80
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★     45.51
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★+     48.96
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
4.31 
Earnings Rating
Strong Buy
Market Cap132.38M 
Earnings Date
4th Aug 2022
Alpha-0.04 Standard Deviation0.18
Beta2.23 

Today's Price Range

2.843.14

52W Range

2.3016.45

5 Year PE Ratio Range

-9.30-10.60

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
8.45%
1 Month
-19.35%
3 Months
-24.82%
6 Months
-60.61%
1 Year
-80.26%
3 Years
-79.42%
5 Years
-87.34%
10 Years
-

TickerPriceChg.Chg.%
CLLS2.91-0.3000-9.35
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Financial StrengthValueIndustryS&P 500US Markets
3.60
3.70
0.31
0.52
-20.60
Leverage Ratio 1.70
ProfitabilityValueIndustryS&P 500US Markets
6.00
-412.80
-357.70
-445.20
-86.60
RevenueValueIndustryS&P 500US Markets
33.39M
0.73
78.83
15.09
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.62-0.70-12.90
Q04 2021-1.05-0.5547.62
Q03 2021-0.82-0.820.00
Q02 2021-0.75-0.88-17.33
Q01 2021-0.82-0.2865.85
Q04 2020-1.01-0.955.94
Q03 2020-0.69-0.71-2.90
Q02 2020-0.73-0.76-4.11
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.559.84Positive
9/2022 QR-0.59-3.51Negative
12/2022 FY-2.312.53Positive
12/2023 FY-1.199.85Positive
Next Report Date4th Aug 2022
Estimated EPS Next Report-0.55
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume174.11K
Shares Outstanding45.49K
Shares Float45.49M
Trades Count1.23K
Dollar Volume518.63K
Avg. Volume160.03K
Avg. Weekly Volume180.46K
Avg. Monthly Volume151.72K
Avg. Quarterly Volume147.92K

Cellectis S.A. (NASDAQ: CLLS) stock closed at 3.21 per share at the end of the most recent trading day (a 2.88% change compared to the prior day closing price) with a volume of 72.80K shares and market capitalization of 132.38M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 264 people. Cellectis S.A. CEO is Andre Choulika.

The one-year performance of Cellectis S.A. stock is -80.26%, while year-to-date (YTD) performance is -60.47%. CLLS stock has a five-year performance of -87.34%. Its 52-week range is between 2.3 and 16.45, which gives CLLS stock a 52-week price range ratio of 4.31%

Cellectis S.A. currently has a PE ratio of -1.00, a price-to-book (PB) ratio of 0.70, a price-to-sale (PS) ratio of 4.38, a price to cashflow ratio of 265.50, a PEG ratio of 2.32, a ROA of -35.08%, a ROC of -38.32% and a ROE of -61.24%. The company’s profit margin is -86.60%, its EBITDA margin is -357.70%, and its revenue ttm is $33.39 Million , which makes it $0.73 revenue per share.

Of the last four earnings reports from Cellectis S.A., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.55 for the next earnings report. Cellectis S.A.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Cellectis S.A. is Moderate Buy (2.14), with a target price of $15.71, which is +439.86% compared to the current price. The earnings rating for Cellectis S.A. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cellectis S.A. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cellectis S.A. has a Neutral technical analysis rating based on Technical Indicators (ADX : 24.20, ATR14 : 0.27, CCI20 : 34.18, Chaikin Money Flow : 0.02, MACD : -0.13, Money Flow Index : 57.02, ROC : 1.90, RSI : 52.04, STOCH (14,3) : 94.79, STOCH RSI : 1.00, UO : 63.16, Williams %R : -5.21), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cellectis S.A. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (57.14 %)
4 (57.14 %)
3 (42.86 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (28.57 %)
2 (28.57 %)
4 (57.14 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (14.29 %)
1 (14.29 %)
0 (0.00 %)
Summary RatingModerate Buy
2.14
Moderate Buy
2.14
Moderate Buy
2.14

Cellectis S.A.

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. The company reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

CEO: Andre Choulika

Telephone: +33 181691600

Address: 8 rue de la Croix Jarry, Paris 75013, , FR

Number of employees: 264

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

62%38%

Bearish Bullish

60%40%

TipRanks News for CLLS

Sun, 15 May 2022 14:19 GMT Cellectis SA (CLLS) Gets a Hold Rating from William Blair

- TipRanks. All rights reserved.

Mon, 11 Apr 2022 16:25 GMT Analysts Offer Insights on Healthcare Companies: Cellectis SA (CLLS) and Nuvectis Pharma (NVCT)

- TipRanks. All rights reserved.

Tue, 08 Mar 2022 06:37 GMT Cellectis SA (CLLS) Receives a Buy from JMP Securities

- TipRanks. All rights reserved.

News

Stocktwits